BioVersys AG (BIOV)
SIX
Real-time Data
07:00 AM
Day's Range
25.0052 wk Range
21.20Overview - BIOV - BioVersys AG
Key Statistics
Valuation
Enterprise Value
84.25M
P/E (Trailing)
‪-6.42‬
P/E (Forward)
‪-4.26‬
PEG Ratio
‪-4.26‬
Price / Sales (TTM)
‪45.67‬
Price / Book
‪2.42‬
EV / EBITDA
‪-4.23‬
Profitability
Profit Margin
‪-386.62%‬
Operating Margin
‪-406.48%‬
Return on Assets
‪-19.86%‬
Return on Equity
‪-61.93%‬
Ownership
Shares Outstanding
5.84M
Float
3.86M
Held by Insiders
‪33.71%‬
Held by Institutions
‪12.84%‬
Price stats
50-Day Avg
‪26.78‬
200-Day Avg
‪25.77‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
4 analysts
Market Cap - BIOV - BioVersys AG
Peers - BIOV - BioVersys AG
Peer Comparison
Compared with companies in Biotechnology listed on SIX.
- BIOVSIXBioVersys AG147.36MMarket Cap+2.78%52-week change-6.50P/E (Trailing)‪-386.62%‬Profit Margin
- BIONSIXBB Biotech AG3.06BMarket Cap+42.25%52-week change2.26P/E (Trailing)‪127.31%‬Profit Margin
- BSLNSIXBasilea Pharmaceutica Ltd800.76MMarket Cap+28.27%52-week change20.57P/E (Trailing)‪21.17%‬Profit Margin
- ADXNSIXAddex Therapeutics Ltd6.28MMarket Cap-38.65%52-week change-0.67P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - BIOV - BioVersys AG
About
BioVersys AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, specializing in the research and development of small molecules with novel mechanisms of action to combat antimicrobial resistance (AMR). The company targets serious life-threatening infections caused by multi-drug…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
